6th IAS Conference On HIV Pathogenesis, Treatment and Prevention

Controversies in HIV Cure Research MOSA02

Organiser: amfAR, The Foundation for AIDS Research and the International AIDS Society (IAS)
Type:
Non-Commercial Satellite Back
Venue: SR 3
Time: 18:30 - 20:30, 18.07.2011
Code: MOSA02
Chairs: Rowena Johnston, United States
Steven Deeks, United States
Rafick-Pierre Sékaly, Canada
Mark Harrington, United States
Françoise Barré-Sinoussi, France

While it is known that antiretroviral therapy does not cure HIV infection, several controversies in the field of HIV cure research remain unresolved and have the potential to redirect lines of scientific inquiry including strategies aimed at curing HIV infection. In this session, basic and clinical research experts will present evidence for each side of the debates around three controversies drawn from basic, preclinical and clinical research. A moderator for each debate will pose questions to each speaker and field questions from the audience.



Presentations in this session:

18:30
Introductions



18:45

Powerpoint
Is there ongoing replication under HAART?
Presented by Mario Stevenson, United Kingdom
Frank Maldarelli, United States



18:55
Discussion



19:25

Powerpoint
Will cell and animal models be informative in planning clinical trials for a cure (or will we only learn from doing the trials)?
Presented by Guido Silvestri, United States
Alan Landay, United States



19:30
Discussion



20:00

Powerpoint
Are we most likely to cure HIV with gene therapy?
Presented by Keith R. Jerome, United States
Sharon Lewin, Australia



20:05
Discussion



20:25

Powerpoint
Closing
Presented by Françoise Barré-Sinoussi, France





Powerpoints presentations
Is there ongoing replication under HAART? - Mario Stevenson

Will cell and animal models be informative in planning clinical trials for a cure (or will we only learn from doing the trials)? - Guido Silvestri
Will cell and animal models be informative in planning clinical trials for a cure (or will we only learn from doing the trials)? - Alan Landay

Are we most likely to cure HIV with gene therapy? - Sharon Lewin
Are we most likely to cure HIV with gene therapy? - Keith R. Jerome

Closing - Françoise Barré-Sinoussi



   

    The organizers reserve the right to amend the programme.


Contact Us | Site map © 2011 International AIDS Society